What groups of people with direct spinal disease are not suitable for treatment with biological agents?

The following categories of direct spinal disease are generally not suitable for the use of biological agents:Patients with active infections• Examples of types of infection: if the patient is suffering from active tuberculosis, the tuberculosis bacteria is active in the body, and the use of biological agents may further inhibit the immune function of the organism, leading to the spread of the tuberculosis stoves, exacerbating the conditions and making it more difficult to control the tuberculosis infection; similarly, active pneumonia (whether bacterial, viral or fungal pneumonia), active skin soft tissue infections (e.g., hives, etc.), urinary system infections (especially in the case of acute kidney infections) and intraperitoneal infections are not suitable for immediate use of biological agents. Because biological agents interfere with normal human immune defence mechanisms, the body ‘ s ability to combat infection is reduced, it is not conducive to the cure of infection and may even cause serious infections of a systemic nature. There are severe immune deficiencies.• Examples: for example, when people living with AIDS, their own body immune system is severely damaged, the number and function of immunosuppressive cells is significantly reduced and the CD4+T lymphocyte count is at a very low level, the use of biological agents, while inhibiting inflammatory tracts, may further weaken pre-existing immune functions, make them more vulnerable to various pathogens, increase the risk of opportunistic infections (e.g. pneumocococcal pneumonia, bowel encephalitis, etc.) and seriously threaten life health. In addition, patients who have undergone physical organ transplants (e.g. kidney transplants, liver transplants, etc.) and who have sustained high doses of immunosuppressants to maintain the stable functioning of transplant organs are also in a state of high inhibition, and are similarly not in a position to use biological agents for the treatment of high-relative spinal tracts in order to avoid the emergence of uncontrolled infections or to affect the survival of transplanted organs. Severe cardiovascular disease and unstable condition• Note: For example, in the recent past (generally within 3 – 6 months), myocardial infarction has occurred, the heart function is in a very precarious state, or there is a serious uncontrolled cardiac failure (cardial function grade III or IV, etc.), the use of biological agents may have a potential risk of cardiovascular malactivation, and the use of biological agents may be difficult for the patient to cope with complications such as infections that may occur during the use of biological agents, which is detrimental to the recovery of the patient’s condition and to the stability of his health as a whole. He has severe liver and kidney incompetence.• Indicator: If a patient’s liver function indicators (e.g., e.g., e.g., diarrhea, e.g., e.g., diarrhea, etc., are several or more times higher, and chordrin is noticeably abnormal) indicate a serious disease in the liver, accompanied by visible signs of condensation, hepatophiliasis, or renal function, hemorrhagic acetic anhydride has risen to a very high level (e.g., high blood acetic anhydride corresponding to the fifth stage of chronic renal disease, accompanied by low urine, no urine, etc.), it has become difficult to maintain normal metabolism and internal stability of the organism, and the physical metabolism and excretion of the drug are severely impaired, the use of biological agents can increase the liver and kidney burden, lead to further deterioration of liver and kidney damage and the failure to effectively perform the normal effects of drug treatment diseases, which are often inappropriate for the use of biological agents and require improvement of the liver and kidney function. Patients allergic to biological agents• Examples of allergies: If a patient has experienced severe allergies in the past when using a biological agent, such as high levels of gill measles, itching, respiratory difficulties, edema, blood pressure reduction, etc., or delayed allergies, in the form of rashes, fever, increased cortex pains, etc., during a period of time after the drug, then biological agents containing the element of allergies will certainly no longer be used, and extreme care will also be required in the use of similar mechanisms or structurally similar biological agents, which will generally be determined by means of assessments such as detailed allergy tests. History of malignant neoplasm (near term or under treatment)• Information note: Biological agents are generally not recommended for newly diagnosed malignant tumours (e.g. lung, stomach, lymphoma, etc.), patients in active treatment stages such as surgery, chemotherapy, decomposition, or, although they have a previous history of malignant tumours, they are at a high risk of relapse and need to be closely monitored for follow-up visits (e.g. within 2-3 years of some more malignant tumours). Because some biological agents may have potential effects on the growth, growth, etc. of tumour cells, or affect the immune response to tumours of organisms, their use may increase the risk of tumour re-emergence and transfer, to the detriment of patients ‘ tumour control and overall health security. The doctor makes a thorough and comprehensive assessment of the patient ‘ s specific circumstances and makes a careful determination as to whether the patient is fit to use biological agents for the treatment of direct spinal disease.